USPTO Examiner MCDOWELL BRIAN E - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18917653NLRP3 INFLAMMASOME INHIBITORSOctober 2024March 2025Allow511YesNo
18804311NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVESAugust 2024January 2025Allow511YesNo
18777202PARP1 INHIBITORS AND USES THEREOFJuly 2024December 2024Allow510NoNo
187367105-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSJune 2024October 2024Allow510NoNo
186235445-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024September 2024Allow510NoNo
186238085-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024June 2024Allow300YesNo
186188245-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSMarch 2024November 2024Allow711YesNo
18692791AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFORMarch 2024March 2025Abandon1321YesNo
18688683THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDEMarch 2024March 2025Allow1311YesNo
18586620TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORSFebruary 2024August 2024Allow611YesNo
184346017-(4-((5-(2-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDFebruary 2024April 2024Allow200YesNo
184304002-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow610NoNo
18393915SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSDecember 2023August 2024Allow711NoNo
18391047PYRAZOLOPYRIMIDINE COMPOUNDSDecember 2023June 2025Abandon1801NoNo
18536912PYRROLO[3,2-C]QUINOLINE-2,3-DIONE COMPOUNDS AS CK2 INHIBITORSDecember 2023April 2024Allow411YesNo
18533073PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow311NoNo
18533067PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow301YesNo
18532293PYRAZINE COMPOUNDDecember 2023May 2025Abandon1701NoNo
183865455-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023March 2024Allow411NoNo
183828052-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023August 2024Abandon911NoNo
18377125ASK1 INHIBITING AGENTSOctober 2023May 2025Allow1911NoNo
18372115BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOFSeptember 2023April 2024Allow711YesNo
18368362Pyrimidine Derivative, Method For Preparing Same And Use Thereof In MedicineSeptember 2023April 2025Allow1911NoNo
18244644PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTSSeptember 2023January 2024Allow411YesNo
18244281BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOFSeptember 2023November 2023Allow310NoNo
18242753PYRROLO[3,2-C]QUINOLINE COMPOUNDS AS CK2 INHIBITORSSeptember 2023February 2024Allow511NoNo
182413837-(4-((5-(BENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUNDSeptember 2023February 2024Allow521YesNo
18240853HDAC INHIBITOR SOLID STATE FORMSAugust 2023August 2024Allow1100NoNo
18455865HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORSAugust 2023June 2025Allow2211YesNo
18236458SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSAugust 2023November 2023Allow301YesNo
182349735-(3-SUBSTITUTED PHENYL)-PYRIMIDO[4,5-d]PYRIMIDINE-2,4,7(1H,3H,8H)-TRIONE DERIVATIVES AS ANTICANCER AGENTSAugust 2023January 2024Allow511YesNo
182320125-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSAugust 2023September 2024Abandon1321NoNo
18353370INHIBITORS OF NLRP3 INFLAMMASOMEJuly 2023May 2025Allow2211YesNo
18352078MK2 INHIBITORS AND USES THEREOFJuly 2023November 2023Allow410NoNo
18333262HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1 DISEASESJune 2023June 2025Allow2411NoNo
18333459PRODRUG OF PYRROLIDONE DERIVATIVES AS GLUCOKINASE ACTIVATORJune 2023March 2024Allow911YesNo
18331758PYRIMIDINE SMALL-MOLECULE COMPOUND AND APPLICATION THEREOFJune 2023November 2023Allow501YesNo
18310463CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOFMay 2023May 2025Abandon2411NoNo
18309164NOVEL PYRIMIDINES AS EGFR-INHIBITORS AND METHODS OF TREATING DISORDERSApril 2023February 2025Allow2211YesNo
18306236RING-MODIFIED PROLINE SHORT PEPTIDE COMPOUND AND USE THEREOFApril 2023May 2024Allow1321YesNo
18133666CRYSTALLINE SUBSTITUTED PYRAZINES AS PGI2 RECEPTOR AGONISTSApril 2023July 2024Allow1501NoNo
18126646ENZYME INHIBITORSMarch 2023October 2024Abandon1901NoNo
18125449PYRROLO[3,4-B]QUINOLINE COMPOUNDS AS ANTIBACTERIAL AGENTSMarch 2023August 2023Allow511YesNo
18184766COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOFMarch 2023May 2025Allow2611YesNo
18121318Chemically Coupled Transporter for Low-Hydrophobicity Bioactive Drugs into the Central Nervous SystemMarch 2023December 2023Allow911YesNo
18179841DERIVATIVES OF ARYL HYDROCARBON RECEPTOR AGONISTSMarch 2023October 2023Allow721YesNo
18117847COMPOUNDS WITH TUBULIN POLYMERISATION INHIBITORY ACTIVITY AND IMMUNOMODULATORY PROPERTIESMarch 2023March 2025Allow2521NoNo
18115314AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOFFebruary 2023September 2023Allow611NoNo
18176107Porphyrin Compounds and Compositions Useful for Treating CancerFebruary 2023June 2025Abandon2711NoNo
18110626HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORSFebruary 2023September 2024Abandon1901NoNo
18105427Belumosudil Metabolites and Uses Thereof In The Treatment of Chronic Graft-Versus-Host DiseaseFebruary 2023December 2023Allow1011YesNo
18104655PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSISFebruary 2023April 2025Allow2711NoNo
18162127FGFR INHIBITORS AND METHODS OF USE THEREOFJanuary 2023May 2023Allow300NoNo
18102359PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSJanuary 2023October 2024Abandon2101NoNo
18160240ORGANIC MOLECULES FOR USE IN OPTOELECTRONIC DEVICESJanuary 2023May 2025Allow2721YesNo
18099770PARP1 INHIBITORS AND USES THEREOFJanuary 2023November 2023Allow921YesNo
18151688PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORSJanuary 2023April 2025Allow2711NoNo
18003849ORGANIC COMPOUND AND ELECTRONIC DEVICE AND ELECTRONIC APPARATUS THEREOFDecember 2022June 2024Allow1721YesNo
18066507METHODS AND COMPOSITIONS FOR TARGETING PD-L1December 2022April 2025Allow2811YesNo
18080566HDAC INHIBITOR SOLID STATE FORMSDecember 2022August 2023Allow811YesNo
18079617PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSDecember 2022January 2024Allow1321NoNo
18075513SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSDecember 2022July 2023Allow811YesNo
18075853NITROGEN CONTAINING HETEROCYCLES AS CDK12 INHIBITORSDecember 2022March 2025Allow2821YesNo
18075270PTERIDINONE COMPOUNDS AND USES THEREOFDecember 2022January 2025Allow2610NoNo
17980186COMPOSITIONS RELATED TO SUBSTITUTED PYRAZINES AS CTPS INHIBITORSNovember 2022May 2025Allow3011YesNo
17968408Methods and Compositions of 4-Substituted Benzoylpiperazine-1-Substituted Carbonyls as Beta-Catenin/B-Cell Lymphoma 9 ImhibitorsOctober 2022January 2025Allow2711NoNo
179658432,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPYOctober 2022March 2025Allow2911YesNo
17957584AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOFSeptember 2022August 2023Abandon1111NoNo
17946236CRYSTALLINE FORMS OF PIPERAZINE-1,4-DIYLBIS((6-(1H-BENZO[D]IMIDAZO-2-YL)PYRIDIN-2YL)METHANONE)September 2022February 2025Allow2911YesNo
17932151Nitrile-Containing Antiviral CompoundsSeptember 2022October 2024Abandon2611NoNo
17930895INHIBITORS OF NLRP3 INFLAMMASOMESeptember 2022February 2023Allow621YesNo
17939375PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVESSeptember 2022July 2024Allow2211NoNo
17900071COMPOUNDS AND METHOD FOR PREPARING THE SAMEAugust 2022July 2023Allow1121YesNo
17899207NOVEL PYRIDAZINESAugust 2022January 2025Abandon2911NoNo
17897667CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOFAugust 2022May 2023Allow811YesNo
17892463LANCL LIGANDSAugust 2022April 2025Allow3211YesNo
17887424FUSED RING HETEROARYL COMPOUNDS AND USE THEREOFAugust 2022January 2025Allow2921YesNo
17885683SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERSAugust 2022November 2024Abandon2711NoNo
17868567MK2 INHIBITORS AND USES THEREOFJuly 2022April 2023Allow911NoNo
17859827INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFJuly 2022September 2023Abandon1421NoNo
17846799SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORSJune 2022March 2025Abandon3301NoNo
17841172INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFJune 2022May 2023Abandon1111YesNo
17806371INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFJune 2022March 2023Allow921YesNo
17833341PSILOCIN DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERSJune 2022January 2023Allow711YesNo
17827491SOLID FORMS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND SALTS THEREOF, AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAMEMay 2022April 2025Allow3511NoNo
17749517PROTACS TARGETING CORONAVIRUS 3CL PROTEASE AND PREPARATION METHOD AND APPLICATION THEREOFMay 2022September 2022Allow411YesNo
17747925CYCLOOLEFIN SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USEMay 2022July 2024Allow2511YesNo
17747261LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDSMay 2022July 2024Allow2611YesNo
17736866HETEROCYCLIC COMPOUNDS FOR INHIBITING TYK2 ACTIVITIESMay 2022October 2022Allow511NoNo
17733650ALK-5 INHIBITORS AND USES THEREOFApril 2022April 2023Allow1111YesNo
17660270Nitrile-Containing Antiviral CompoundsApril 2022June 2022Allow201NoNo
17720074CRYSTALLINE COMPOSITION OF TILDACERFONT AND METHODS OF USE AND PREPARATION THEREOFApril 2022March 2023Allow1111YesNo
17713946SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORSApril 2022October 2024Abandon3121YesNo
17711876CRYSTALS OF TETRAHYDRONAPHTHYL UREA DERIVATIVEApril 2022July 2024Allow2810NoNo
17710386COMPOSITIONS AND METHODS FOR VIRAL SENSITIZATIONMarch 2022September 2024Allow2911NoNo
17701856INHIBITORS OF NLRP3 INFLAMMASOMEMarch 2022March 2023Allow1121NoNo
17696922SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORSMarch 2022October 2023Allow1911YesNo
17684030BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOFMarch 2022April 2025Allow3821NoNo
17683146MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOFFebruary 2022July 2024Allow2810NoNo
17671806PYRROLIDINE COMPOUNDSFebruary 2022June 2025Allow4011NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MCDOWELL, BRIAN E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
4
(80.0%)
Examiner Reversed
1
(20.0%)
Reversal Percentile
29.8%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
64
Allowed After Appeal Filing
15
(23.4%)
Not Allowed After Appeal Filing
49
(76.6%)
Filing Benefit Percentile
28.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MCDOWELL, BRIAN E - Prosecution Strategy Guide

Executive Summary

Examiner MCDOWELL, BRIAN E works in Art Unit 1624 and has examined 1,462 patent applications in our dataset. With an allowance rate of 67.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 23 months.

Allowance Patterns

Examiner MCDOWELL, BRIAN E's allowance rate of 67.3% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MCDOWELL, BRIAN E receive 1.49 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MCDOWELL, BRIAN E is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.2% benefit to allowance rate for applications examined by MCDOWELL, BRIAN E. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.4% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.7% of cases where such amendments are filed. This entry rate is in the 48% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 16.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 24% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 86.5% of appeals filed. This is in the 77% percentile among all examiners. Of these withdrawals, 78.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 53.8% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.1% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.1% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.